Floatz logo

Sargramostim

Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8

Mayo Clinicprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BB
Pembrolizumab
Mayo Clinic
Phase 3BB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4B
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3B

View all 44 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →